BCACP Cardiovascular Disease Management 3

Question 1

A patient with type 2 diabetes and established ASCVD has an A1c of 8.2%. Which antidiabetic agent provides the greatest cardiovascular mortality benefit in this scenario?

Accepted Answer

Empagliflozin or liraglutide

Answer

SGLT2 inhibitors (empagliflozin) and GLP-1 receptor agonists (liraglutide) have demonstrated cardiovascular mortality reduction in patients with T2DM and established ASCVD in landmark trials.

Question 2

A patient on aspirin 81 mg daily for secondary prevention develops a GI bleed. After recovery, what is the most appropriate management of antiplatelet therapy?

Accepted Answer

Resume aspirin with a proton pump inhibitor

Answer

Aspirin should be resumed for secondary cardiovascular prevention with concomitant PPI therapy to reduce recurrent GI bleeding risk, as the cardiovascular benefit outweighs GI risk when managed appropriately.

Question 3

What is the mechanism by which ivabradine reduces symptoms in stable heart failure with reduced ejection fraction?

Accepted Answer

Selectively inhibits the If (funny) current in the SA node, reducing heart rate

Answer

Ivabradine selectively inhibits the If current in the sinoatrial node, slowing heart rate without affecting myocardial contractility or blood pressure.

Question 4

A patient with peripheral arterial disease (PAD) and hypertension asks if beta-blockers are contraindicated. What is the most accurate response?

Accepted Answer

Beta-blockers are not contraindicated in PAD and may be used when indicated for comorbidities

Answer

Current evidence does not support avoiding beta-blockers in PAD; they are indicated for comorbid conditions such as CAD, HF, or post-MI and do not worsen claudication significantly.

Question 5

A patient with HFrEF and iron-deficiency anemia (ferritin <100 ng/mL, transferrin saturation <20%) is being optimized. Which intervention has demonstrated improved symptoms and quality of life?

Accepted Answer

Intravenous ferric carboxymaltose

Answer

Intravenous ferric carboxymaltose has demonstrated improved exercise capacity, symptoms, and quality of life in HFrEF patients with iron deficiency, unlike oral iron which has shown limited benefit.

BCACP - Board Certified Ambulatory Care Pharmacist Exam Practice Test

BCACP - Board Certified Ambulatory Care Pharmacist Exam Practice Test

BCACP Cardiovascular Disease Management 3